PLoS ONE (Jan 2020)

A novel drug repurposing approach for non-small cell lung cancer using deep learning.

  • Bingrui Li,
  • Chan Dai,
  • Lijun Wang,
  • Hailong Deng,
  • Yingying Li,
  • Zheng Guan,
  • Haihong Ni

DOI
https://doi.org/10.1371/journal.pone.0233112
Journal volume & issue
Vol. 15, no. 6
p. e0233112

Abstract

Read online

Drug repurposing is an attractive and pragmatic way offering reduced risks and development time in the complicated process of drug discovery. In the past, drug repurposing has been largely accidental and serendipitous. The most successful examples so far have not involved a systematic approach. Nowadays, remarkable advances in drugs, diseases and bioinformatic knowledge are offering great opportunities for designing novel drug repurposing approach through comprehensive understanding of drug information. In this study, we introduced a novel drug repurposing approach based on transcriptomic data and chemical structures using deep learning. One strong candidate for repurposing has been identified. Pimozide is an anti-dyskinesia agent that is used for the suppression of motor and phonic tics in patients with Tourette's Disorder. However, our pipeline proposed it as a strong candidate for treating non-small cell lung cancer. The cytotoxicity of pimozide against A549 cell lines has been validated.